Swiss biopharmaceutical firm Relief Therapeutics receives Notice of Allowance for EB wound treatment patent in Europe, with protection until 2040; US and China applications pending.

Relief Therapeutics, a Swiss biopharmaceutical firm, has received a Notice of Allowance from the European Patent Office for a patent covering its hypochlorous acid solutions, including the investigational drug RLF-TD011, aimed at treating wounds from epidermolysis bullosa (EB). The patent will protect RLF-TD011 in Europe until 2040, with applications pending in the U.S. and China. The drug has received orphan drug designation from the FDA, offering potential market exclusivity.

October 21, 2024
4 Articles